HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sae-Won Han Selected Research

N- (4- (3- (1H- 1,2,4- triazol- 1- yl)- 4- (3,4,5- trimethoxybenzoyl)phenyl)thiazol- 2- yl)- 2- amino- 3- methylbutanamide

10/2021A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.
1/2016Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sae-Won Han Research Topics

Disease

96Neoplasms (Cancer)
05/2024 - 06/2006
45Colorectal Neoplasms (Colorectal Cancer)
12/2023 - 06/2011
40Breast Neoplasms (Breast Cancer)
04/2023 - 10/2008
29Stomach Neoplasms (Stomach Cancer)
01/2019 - 05/2008
16Neoplasm Metastasis (Metastasis)
01/2020 - 07/2009
14Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2013 - 01/2005
12Colonic Neoplasms (Colon Cancer)
01/2023 - 10/2011
10Adenocarcinoma
01/2018 - 11/2006
8Biliary Tract Neoplasms (Biliary Tract Cancer)
10/2017 - 05/2011
7Pancreatic Neoplasms (Pancreatic Cancer)
10/2021 - 10/2011
7Triple Negative Breast Neoplasms
05/2019 - 03/2011
6Rectal Neoplasms (Rectal Cancer)
08/2023 - 12/2013
5Disease Progression
04/2023 - 03/2013
5Lung Neoplasms (Lung Cancer)
01/2022 - 11/2007
5Hepatocellular Carcinoma (Hepatoma)
01/2021 - 12/2010
4Pathologic Complete Response
08/2023 - 12/2012
4Microsatellite Instability
01/2019 - 05/2013
3Residual Neoplasm
01/2023 - 11/2014
3Margins of Excision
07/2019 - 12/2012
3Hypersensitivity (Allergy)
11/2018 - 05/2014
3Obesity
10/2017 - 12/2012
3Carcinogenesis
01/2013 - 11/2007
2Neurofibromatosis 1 (Neurofibromatosis Type I)
01/2023 - 01/2020
2Circulating Neoplastic Cells
01/2021 - 01/2017
2Body Weight Changes
11/2020 - 10/2015
2Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2018 - 09/2011
2Body Weight (Weight, Body)
10/2017 - 10/2015
2Cholangiocarcinoma
11/2016 - 10/2015
2Weight Loss (Weight Reduction)
04/2016 - 07/2014
2Ataxia Telangiectasia (Louis Bar Syndrome)
01/2016 - 01/2014

Drug/Important Bio-Agent (IBA)

21Oxaliplatin (Eloxatin)FDA LinkGeneric
08/2023 - 05/2008
19Fluorouracil (Carac)FDA LinkGeneric
12/2023 - 05/2008
16ErbB Receptors (EGF Receptor)IBA
04/2019 - 01/2005
14Biomarkers (Surrogate Marker)IBA
01/2022 - 10/2011
11Proteins (Proteins, Gene)FDA Link
01/2023 - 07/2011
11Tyrosine Kinase InhibitorsIBA
07/2018 - 11/2007
11Trastuzumab (Herceptin)FDA Link
09/2016 - 01/2011
9Leucovorin (Folinic Acid)FDA Link
12/2023 - 05/2008
9GemcitabineFDA Link
10/2021 - 06/2006
8Cetuximab (Erbitux)FDA Link
12/2023 - 03/2008
8taxaneIBA
04/2023 - 01/2012
8DNA (Deoxyribonucleic Acid)IBA
01/2023 - 03/2010
8Hormones (Hormone)IBA
01/2020 - 05/2011
8Lapatinib (GW572016)FDA Link
02/2015 - 03/2008
8Gefitinib (Iressa)FDA Link
02/2012 - 01/2005
7Irinotecan (Camptosar)FDA LinkGeneric
12/2023 - 10/2013
7Cisplatin (Platino)FDA LinkGeneric
10/2021 - 06/2011
7PlatinumIBA
11/2018 - 12/2010
7human ERBB2 proteinIBA
11/2013 - 10/2008
6Capecitabine (Xeloda)FDA Link
08/2023 - 01/2011
5Circulating Tumor DNAIBA
08/2023 - 01/2020
5regorafenibIBA
07/2023 - 01/2015
5Calcibiotic Root Canal SealerIBA
11/2022 - 10/2015
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 09/2009
5Estrogen ReceptorsIBA
12/2015 - 10/2008
5Paclitaxel (Taxol)FDA LinkGeneric
07/2015 - 03/2012
5Doxorubicin (Adriamycin)FDA LinkGeneric
04/2013 - 09/2011
4AnthracyclinesIBA
04/2023 - 08/2012
4B7-H1 AntigenIBA
01/2021 - 11/2016
4thiamine triphosphorate (TTP)IBA
01/2018 - 08/2010
4Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2016 - 05/2011
4Epidermal Growth Factor (EGF)IBA
11/2013 - 11/2006
4Thymidylate SynthaseIBA
07/2011 - 06/2009
3AntigensIBA
12/2022 - 07/2017
3Carcinoembryonic AntigenIBA
01/2020 - 07/2017
3HM781-36BIBA
07/2018 - 03/2011
3Aromatase InhibitorsIBA
10/2017 - 07/2012
3CytokinesIBA
03/2017 - 12/2013
3ChromatinIBA
04/2016 - 01/2016
3MethyltransferasesIBA
04/2016 - 06/2010
3Histone Deacetylase InhibitorsIBA
03/2015 - 12/2011
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2015 - 09/2011
3Docetaxel (Taxotere)FDA Link
04/2013 - 09/2011
2GC1118IBA
12/2023 - 01/2019
2Bevacizumab (Avastin)FDA Link
03/2023 - 12/2016
2Neurofibromin 1 (Neurofibromin)IBA
01/2023 - 01/2020
2Monoclonal AntibodiesIBA
12/2022 - 08/2012
2AntibodiesIBA
12/2022 - 01/2019
2N- (4- (3- (1H- 1,2,4- triazol- 1- yl)- 4- (3,4,5- trimethoxybenzoyl)phenyl)thiazol- 2- yl)- 2- amino- 3- methylbutanamideIBA
10/2021 - 01/2016
2Sorafenib (BAY 43-9006)FDA Link
01/2021 - 04/2011
2MucinsIBA
07/2019 - 01/2019
2Phenobarbital (Luminal)FDA Link
05/2019 - 01/2016
2Antineoplastic Agents (Antineoplastics)IBA
04/2019 - 01/2018
2TubulinIBA
07/2017 - 03/2010
2TOR Serine-Threonine KinasesIBA
04/2017 - 12/2010
2Phosphoric Monoester Hydrolases (Phosphatases)IBA
04/2017 - 04/2006
2TensinsIBA
04/2017 - 04/2006
2CohesinsIBA
01/2016 - 01/2016

Therapy/Procedure

60Drug Therapy (Chemotherapy)
08/2023 - 01/2005
33Therapeutics
05/2024 - 11/2007
14Neoadjuvant Therapy
08/2023 - 03/2011
11Adjuvant Chemotherapy
01/2023 - 03/2010
9Radiotherapy
08/2023 - 01/2012
8Chemoradiotherapy
08/2023 - 12/2012
8Adjuvant Chemoradiotherapy
04/2017 - 04/2012
7Combination Drug Therapy (Combination Chemotherapy)
09/2014 - 05/2008
3Precision Medicine
05/2024 - 01/2022
3Adjuvant Radiotherapy
01/2016 - 12/2012
3Maintenance Chemotherapy
07/2015 - 09/2012
2Palliative Care (Palliative Therapy)
12/2017 - 01/2012